Journal of International Psychiatry

[Abstract] Objective: To analyze the efficacy of clopidogrel and fluvastatin in the treatment of cerebral infarction and its influence on depression and anxiety scores. Methods: 96 patients with cerebral infarction in our hospital from January 2019 to January 2021 were selected and divided into two groups according to "different treatment methods". 48 patients in the reference group were treated with routine clinical treatment, and 48 patients in the experimental group were treated with clopidogrel and fluvastatin. The clinical efficacy, NIHSS score, serum MDA, SOD, total incidence of adverse reactions, HAMA score and HAMD score of the two groups were compared. Results: The clinical total effective rate of the experimental group (91.67%) was higher than that of the reference group (66.67%), the NIHSS score, serum SOD, HAMA score and HAMD score of the experimental group were lower than those of the reference group after treatment, and the serum MDA of the experimental group was higher than that of the reference group after treatment, the differences were statistically significant (P<0.05). The total incidence of adverse reactions in the experimental group (6.25%) was higher than that in the control group (8.33%), P > 0.05. Conclusion: clopidogrel and fluvastatin can effectively reduce the degree of neurological impairment and adverse emotions in patients with cerebral infarction, regulate the serum MDA and SOD concentrations, and have less adverse reactions.

[Key words] clopidogrel; Fluvastatin; Cerebral infarction; Clinical effect; Bad mood